METHOD FOR PERSONALIZED COMBINED TREATMENT OF PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER STAGE II-III Russian patent published in 2022 - IPC A61K31/282 A61K31/337 A61K31/4745 A61K31/704 A61K31/7068 A61P35/00 G01N33/58 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology, and can be used for personalized combined treatment of stage II-III non-small cell lung cancer. A radical anatomical resection is performed with mediastinal ipsilateral lymph node dissection with intraoperative radiation therapy with a single dose of ROD 10.0 Gy. In the postoperative period, when the expression level of the ERCC1 monoresistance gene is less than 1.5, adjuvant chemotherapy is performed using carboplatin at a dose of AUC6 in combination with a cytostatic agent, the choice of which is as follows: at the level of RRM1 or TYMS less than 1.5, ABCC5 less than 1, adjuvant chemotherapy is performed using carboplatin and gemcitabine; at a TOR1 level of more than 3, adjuvant chemotherapy is performed using carboplatin and irinotecan; at a TUBB3 level of 1.5-2.5, adjuvant chemotherapy is performed using carboplatin and vinorelbine; at the level of TOR2a more than 3, adjuvant chemotherapy is performed using carboplatin and doxorubicin; at a BRCA1 level of more than 2, adjuvant chemotherapy is performed using carboplatin and paclitaxel.

EFFECT: method provides reduction of complications caused by metastasis due to adjuvant chemotherapy using carboplatin in combination with various cytostatics.

1 cl, 4 ex